Ladies and gentlemen, I apologize for the technical difficulties. Mr. Clawson, please continue.
Matt ClawsonThank you, Alicia. I’m sorry folks. It seems that the provider had a system-wide failure, so anyway, without further ado and apologies here, we’ll begin over with forward-looking statements to make sure we got that all covered. Before I turn the call over to management, please remember that our prepared remarks and responses to questions will contain forward-looking statements that are subject to a number of risks and uncertainties. Examples of such statements includes statements about the expected timing of commercial availability of our Magellan Vascular Robotic System, the level of clinical interest in our Vascular Robotic System, and expectations regarding commercial success of our Lynx irrigated catheter. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements, include among others, the development of new products and applications of technology are subject to design, engineering, and manufacturing challenges that could delay clinical studies, regulatory filings, and commercialization, potential safety and regulatory issues could delay, suspend, or terminate clinical studies, regulatory approvals, or sales, uncertain timelines, costs, and results of clinical trials, and development of new products, our ability to plan and manage cost reduction or operational efficiency initiatives, the scope and validity of intellectual property rights applicable to products being developed, and our ability to maintain our remedial actions over previously reported material weaknesses and internal controls over financial reporting. These and other risks are described in greater detail under the heading risk factors contained in our periodic SEC filings including our quarterly report form 10-Q filed with the SEC on May 10 th, 2011. Given these uncertainties, you should not place undue reliance on the forward-looking statements retained in this conference call. We take no obligation to revise or update information herein to reflect events or circumstances in the future even if new information becomes available.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV